GSK To Pay $150M To Settle Direct Purchasers' Flonase Suit

Law360, New York (December 19, 2012, 7:50 PM ET) -- GlaxoSmithKline agreed to pay $150 million to end a direct purchaser antitrust class action accusing GSK of filing sham petitions with the U.S. Food and Drug Administration to delay generic alternatives to Flonase nasal spray, Meijer Inc. told a Pennsylvania federal court last week.

In a motion filed Dec. 11 but just recently made available, the direct purchasers Meijer and American Sales Co. asked U.S. District Judge Anita Brody to preliminarily approve the deal. Indirect purchaser plaintiffs have also asked for approval of a class action...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required